Abstract 491P
Background
Furmonertinib (AST2818) is a novel, promising oral third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR sensitive mutations and T790M mutation, which has demonstrated efficacy in NSCLC in previous clinical trials. However, the efficacy and safety of furmonertinib as adjuvant therapy in patients ≥ 65 years old remain unclear.
Methods
Patients who underwent radical lung cancer surgery with EGFR mutations from two independent medical centers were enrolled and received furmonertinib 80mg daily. The adjuvant therapy time (6-36months) depended on patients’pathologic stage and physical conditions. The disease-free survival (DFS), safety and tolerability were evaluated.
Results
This study retrospectively analyzed 101 patients who were pathologically confirmed adenocarcinoma, EGFR mutation-positive (exon 19 deletion/L858R), stage IA2-IIIA NSCLC (60 females, 41 males, ranging in age from 43 to 86 years, with a median age of 65). Among them, 55 cases were ≥ 65 years old (median age 69 years, including 21 ≥ 70 years old), and 46 cases were<65 years old (median age 56.5 years old). All patients were followed at least 10 months, and 68 (67.3%) of them have been followed up for over 2 years, median follow-up time was 22 months. At data cutoff, all patients were alive, only 3 of them had metastasis (CNS, chest wall, and pancreas, respectively). The 2-year DFS rates for patients ≥ 65 years old and<65 years old were 96% and 97%, respectively (p=0.98). During therapy, 39 (38.6%) patients had treatment-related adverse events (TRAEs) of any grade. The most common TRAEs were rash (19/101, 18.8%), mouth ulcer (9/101, 8.9%) ,diarrhea (9/101, 8.9%) and transaminase elevation (5/101, 5.0%). Only 3 (3.0%) patients had TRAEs of grade 3 or higher and 1(1.4%) of them discontinued therapy. There was no significant difference in the incidence of TRAEs of any grade in patients aged ≥ 65 years and < 65 years (30.9% and 47.8%, p=0.08, respectively).
Conclusions
This is the first real-world study to demonstrate that furmonertinib has good efficacy and a tolerable safety profile in elderly patients (≥ 65 years) with completely resected stage I-III NSCLC harboring EGFR mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract